Related Experiment Video

Updated: Oct 27, 2025

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

7.6K

Antitumor effect of dimethyl itaconate on thymic carcinoma by targeting LDHA-mTOR axis

Keitaro Hayashi1, Yoshimasa Nakazato2, Motoshi Ouchi1

  • 1Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, Shimotsuga, Japan.

Life Sciences
|July 22, 2021
PubMed
Abstract

Insights

Dimethyl itaconate (DI) shows promise in treating thymic carcinoma by inhibiting cancer cell growth and promoting apoptosis. This novel strategy targets lactate dehydrogenase A (LDHA) and mechanistic target of rapamycin (mTOR) pathways.

Area of Science:

  • Oncology
  • Biochemistry

Background:

  • Thymic carcinoma is a rare malignancy lacking standard pharmaceutical treatments.
  • Itaconate derivatives, like dimethyl itaconate (DI), are being explored for therapeutic potential.

Purpose of the Study:

  • To investigate the antitumor effects of dimethyl itaconate (DI) on a human thymic carcinoma cell line.
  • To elucidate the molecular mechanisms underlying DI's anti-cancer activity.

Main Methods:

  • Utilized the human thymic carcinoma cell line Ty82.
  • Assessed DI's impact on cell viability, apoptosis, and molecular pathways via Western blotting and immunohistochemistry.

Main Results:

  • DI significantly suppressed Ty82 cell growth and induced apoptosis.
  • DI's effects were mediated by downregulating lactate dehydrogenase A (LDHA), subsequently decreasing mechanistic target of rapamycin (mTOR) activity.
  • DI demonstrated synergistic antitumor effects when combined with a large neutral amino acid transporter 1 (LAT1) inhibitor.

Conclusions:

  • Dimethyl itaconate (DI) represents a potential novel therapeutic strategy for thymic carcinoma.
  • Targeting LDHA and mTOR pathways, alongside LAT1, offers a promising avenue for thymic carcinoma treatment.
Keywords:
Dimethyl itaconateLAT1LDHAThymic carcinomamTOR

More Related Videos

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

3.7K
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

1.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
779
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K